Babak Behnam Azad1, Ala Lisok1, Samit Chatterjee1, John T Poirier2, Mrudula Pullambhatla1, Gary D Luker3, Martin G Pomper4, Sridhar Nimmagadda5. 1. Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland. 2. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 3. Department of Radiology, University of Michigan, Ann Arbor, Michigan; and. 4. Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland. 5. Department of Radiology and Radiological Science, Johns Hopkins University, Baltimore, Maryland Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland snimmag1@jhmi.edu.
Abstract
UNLABELLED: The atypical chemokine receptor ACKR3 (formerly CXCR7), overexpressed in various cancers compared with normal tissues, plays a pivotal role in adhesion, angiogenesis, tumorigenesis, metastasis, and tumor cell survival. ACKR3 modulates the tumor microenvironment and regulates tumor growth. The therapeutic potential of ACKR3 has also been demonstrated in various murine models of human cancer. Literature findings underscore the importance of ACKR3 in disease progression and suggest it as an important diagnostic marker for noninvasive imaging of ACKR3-overexpressing malignancies. There are currently no reports on direct receptor-specific detection of ACKR3 expression. Here we report the evaluation of a radiolabeled ACKR3-targeted monoclonal antibody (ACKR3-mAb) for the noninvasive in vivo nuclear imaging of ACKR3 expression in human breast, lung, and esophageal squamous cell carcinoma cancer xenografts. METHODS: ACKR3 expression data were extracted from Cancer Cell Line Encyclopedia, The Cancer Genome Atlas, and the Clinical Lung Cancer Genome Project. (89)Zr-ACKR3-mAb was evaluated in vitro and subsequently in vivo by PET and ex vivo biodistribution studies in mice xenografted with breast (MDA-MB-231-ACKR3 [231-ACKR3], MDA-MB-231 [231], MCF7), lung (HCC95), or esophageal (KYSE520) cancer cells. In addition, ACKR3-mAb was radiolabeled with (125)I and evaluated by SPECT imaging and ex vivo biodistribution studies. RESULTS: ACKR3 transcript levels were highest in lung squamous cell carcinoma among the 21 cancer type data extracted from The Cancer Genome Atlas. Also, Clinical Lung Cancer Genome Project data showed that lung squamous cell carcinoma had the highest CXCR7 transcript levels compared with other lung cancer subtypes. The (89)Zr-ACKR3-mAb was produced in 80% ± 5% radiochemical yields with greater than 98% radiochemical purity. In vitro cell uptake of (89)Zr-ACKR3-mAb correlated with gradient levels of cell surface ACKR3 expression observed by flow cytometry. In vivo PET imaging and ex vivo biodistribution studies in mice with breast, lung, and esophageal cancer xenografts consistently showed enhanced (89)Zr-ACKR3-mAb uptake in high-ACKR3-expressing tumors. SPECT imaging of (125)I-ACKR3-mAb showed the versatility of ACKR3-mAb for in vivo monitoring of ACKR3 expression. CONCLUSION: Data from this study suggest ACKR3 to be a viable diagnostic marker and demonstrate the utility of radiolabeled ACKR3-mAb for in vivo visualization of ACKR3-overexpressing malignancies.
UNLABELLED: The atypical chemokine receptor ACKR3 (formerly CXCR7), overexpressed in various cancers compared with normal tissues, plays a pivotal role in adhesion, angiogenesis, tumorigenesis, metastasis, and tumor cell survival. ACKR3 modulates the tumor microenvironment and regulates tumor growth. The therapeutic potential of ACKR3 has also been demonstrated in various murine models of humancancer. Literature findings underscore the importance of ACKR3 in disease progression and suggest it as an important diagnostic marker for noninvasive imaging of ACKR3-overexpressing malignancies. There are currently no reports on direct receptor-specific detection of ACKR3 expression. Here we report the evaluation of a radiolabeled ACKR3-targeted monoclonal antibody (ACKR3-mAb) for the noninvasive in vivo nuclear imaging of ACKR3 expression in human breast, lung, and esophageal squamous cell carcinoma cancer xenografts. METHODS:ACKR3 expression data were extracted from Cancer Cell Line Encyclopedia, The Cancer Genome Atlas, and the Clinical Lung Cancer Genome Project. (89)Zr-ACKR3-mAb was evaluated in vitro and subsequently in vivo by PET and ex vivo biodistribution studies in mice xenografted with breast (MDA-MB-231-ACKR3 [231-ACKR3], MDA-MB-231 [231], MCF7), lung (HCC95), or esophageal (KYSE520) cancer cells. In addition, ACKR3-mAb was radiolabeled with (125)I and evaluated by SPECT imaging and ex vivo biodistribution studies. RESULTS:ACKR3 transcript levels were highest in lung squamous cell carcinoma among the 21 cancer type data extracted from The Cancer Genome Atlas. Also, Clinical Lung Cancer Genome Project data showed that lung squamous cell carcinoma had the highest CXCR7 transcript levels compared with other lung cancer subtypes. The (89)Zr-ACKR3-mAb was produced in 80% ± 5% radiochemical yields with greater than 98% radiochemical purity. In vitro cell uptake of (89)Zr-ACKR3-mAb correlated with gradient levels of cell surface ACKR3 expression observed by flow cytometry. In vivo PET imaging and ex vivo biodistribution studies in mice with breast, lung, and esophageal cancer xenografts consistently showed enhanced (89)Zr-ACKR3-mAb uptake in high-ACKR3-expressing tumors. SPECT imaging of (125)I-ACKR3-mAb showed the versatility of ACKR3-mAb for in vivo monitoring of ACKR3 expression. CONCLUSION: Data from this study suggest ACKR3 to be a viable diagnostic marker and demonstrate the utility of radiolabeled ACKR3-mAb for in vivo visualization of ACKR3-overexpressing malignancies.
Authors: A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik Journal: Nature Date: 2001-03-01 Impact factor: 49.962
Authors: Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall Journal: Proc Natl Acad Sci U S A Date: 2007-09-26 Impact factor: 11.205
Authors: Brian Bierie; Christine H Chung; Joel S Parker; Daniel G Stover; Nikki Cheng; Anna Chytil; Mary Aakre; Yu Shyr; Harold L Moses Journal: J Clin Invest Date: 2009-05-18 Impact factor: 14.808
Authors: Preeti Misra; Djamel Lebeche; Hung Ly; Martina Schwarzkopf; George Diaz; Roger J Hajjar; Alison D Schecter; John V Frangioni Journal: J Nucl Med Date: 2008-05-15 Impact factor: 10.057
Authors: Brian A Zabel; Yu Wang; Susanna Lewén; Robert D Berahovich; Mark E T Penfold; Penglie Zhang; Jay Powers; Bretton C Summers; Zhenhua Miao; Bin Zhao; Ali Jalili; Anna Janowska-Wieczorek; Juan C Jaen; Thomas J Schall Journal: J Immunol Date: 2009-07-29 Impact factor: 5.422
Authors: Jennifer M Burns; Bretton C Summers; Yu Wang; Anita Melikian; Rob Berahovich; Zhenhua Miao; Mark E T Penfold; Mary Jean Sunshine; Dan R Littman; Calvin J Kuo; Kevin Wei; Brian E McMaster; Kim Wright; Maureen C Howard; Thomas J Schall Journal: J Exp Med Date: 2006-08-28 Impact factor: 14.307
Authors: Nicole Salazar; Jeffrey C Carlson; Kexin Huang; Yayue Zheng; Cecilia Oderup; Julia Gross; Andrew D Jang; Thomas M Burke; Susanna Lewén; Alexander Scholz; Serina Huang; Leona Nease; Jon Kosek; Michel Mittelbronn; Eugene C Butcher; Hua Tu; Brian A Zabel Journal: Mol Ther Date: 2018-03-06 Impact factor: 11.454
Authors: Barbara Salvatore; Maria Grazia Caprio; Billy Samuel Hill; Annachiara Sarnella; Giovanni Nicola Roviello; Antonella Zannetti Journal: Cancers (Basel) Date: 2019-10-22 Impact factor: 6.639